The company is accelerating its Phase 2 glioblastoma trial and has previously closed an oversubscribed $11.4 million seed financing.
Founders
Mike Wicks
Company Description
Diakonos Oncology is a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers.
Market
Immunotherapy for aggressive cancers
Location
Houston,
Texas,
USA
Coinvestors
Baylor College of Medicine, Brain Tumor Investment Fund, Buttonwood Titan QC Fund